Archive for 2012
Fibrocell Science, Inc. Announces Exclusive License Agreement with UCLA on Dermal Cell Research to Advance the Development of Personalized Cell Therapies
Agreement Furthers an Existing Collaboration That Has Already Yielded Important Breakthroughs in the Identification of Rare Stem Cells and Regenerative Cell Subpopulations in Adult Human Skin EXTON, Pa., May 16, 2012 – Fibrocell Science, Inc. (OTCBB: FCSC) announced today that it has signed an exclusive license agreement with The Regents of the University of California,Read more
Fibrocell Science, Inc. and Top University Investigators Form Scientific Initiative to Assist in Securing Grant Funding for Research to Advance the Development of Personalized Cell Therapies
Group Aims to Facilitate Collaboration Among Scientists, Researchers and Private Sector Exton, PA, May 15, 2012 –Fibrocell Science, Inc. announced today the formation of the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives (CIDMOD) Initiative (www.CIDMOD.org) in collaboration with researchers from a number of different universities across the U.S. The CIDMOD Initiative will facilitate the collaboration ofRead more
Fibrocell Science Submits a Phase II Study Protocol to the FDA To Evaluate the Use of azficel-T in Treating Restrictive Burn Scars
Exton, PA, May 14, 2012 – Fibrocell Science, Inc. (OTCBB: FCSC) announced today that is has submitted to the U.S. Food & Drug Administration (FDA) the company’s Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell’s lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients withRead more
Fibrocell Science Technology Leads to Discovery of Two Rare Adult Stem Cell-Like Subpopulations in Human Skin
-Purification and Expansion of These Cells May Yield Further Research Advances to Exploring Potential Personalized Regenerative Therapies for a Variety of Conditions- EXTON, Pa., May 3, 2012 – In collaboration with Fibrocell Science, Inc., researchers at the University of California, Los Angeles (UCLA) have identified two rare adult stem cell-like subpopulations in adult human skin,Read more
Fibrocell Science, Inc. to Host Investor Conference Call to Discuss First Quarter 2012 Business Update
EXTON, Pa., May 2, 2012 – Fibrocell Science, Inc., an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s business update for the first quarter ended March 31,Read more
Follow Us
